Freemont A J, Byers R J, Taiwo Y O, Hoyland J A
Musculoskeletal Research Group, Stopford Building, University of Manchester, Manchester M13 9PT.
Ann Rheum Dis. 1999 Jun;58(6):357-65. doi: 10.1136/ard.58.6.357.
Chondrocytic matrix metalloproteinases (MMPs) are believed to be important in osteoarthritic cartilage degradation. The cartilage lesion of osteoarthritis (OA) is focal and often progressive. During its development chondrocytes differentially up and down regulate production of mRNA for individual MMPs. This observation has potential implications for understanding the disease processes that lead to progressive cartilage loss in OA and designing appropriate targeted treatment. The complex regulation of MMP mediated effects means there is a pressing need to establish whether visualisation of MMP mRNA or protein equates to enzyme activity. The technique of in situ zymography (ISZ) offers a way of examining diseased human tissue for in vivo production of an excess of degrading enzyme over inhibitor. The primary objective of this study was to assess, and if positive follow, collagen II degrading activity in cartilage during development of the OA lesion. A secondary objective was to assess whether there was any correlation between sites of collagen II degrading activity and expression of the collagenase (MMP-13), recently implicated in type II collagen degredation in this lesion.
Biopsied human normal and osteoarthritic cartilage, showing various degrees of damage, was examined by in situ zymography, with and without enzyme inhibitors, to establish sites of type II collagenase activity. Paired samples were probed for MMP-13 mRNA using 35S-labelled oligonucleotide probes. Comparative analyses were performed.
In situ zymography showed collagen II degrading activity over chondrocytes only in osteoarthritic cartilage. Distribution and amount varied with the extent of cartilage damage and position of chondrocytes, being greatest in deep cartilage and in cartilage lesions where fissuring was occurring. The enzyme causing the degradation behaved as a matrix metalloproteinase. MMP-13 mRNA expression codistributed with the type II collagenase activity.
In OA, chondrocytes can degrade type II collagen. The type II collagen degrading activity varies in site and amount as the cartilage lesion progresses and throughout codistributes with MMP-13 mRNA expression.
软骨细胞基质金属蛋白酶(MMPs)被认为在骨关节炎软骨降解过程中起重要作用。骨关节炎(OA)的软骨损伤是局灶性的,且常常呈进行性发展。在其发展过程中,软骨细胞对单个MMPs的mRNA产生进行差异性上调和下调。这一观察结果对于理解导致OA中软骨进行性丧失的疾病过程以及设计合适的靶向治疗具有潜在意义。MMP介导效应的复杂调控意味着迫切需要确定MMP mRNA或蛋白的可视化是否等同于酶活性。原位酶谱法(ISZ)提供了一种检测患病人体组织中降解酶在体内产生量是否超过抑制剂的方法。本研究的主要目的是评估OA病变发展过程中软骨中II型胶原降解活性,并在结果为阳性时进行后续研究。次要目的是评估II型胶原降解活性部位与胶原酶(MMP - 13)表达之间是否存在任何相关性,最近研究表明MMP - 13与该病变中II型胶原降解有关。
对显示出不同程度损伤的活检人类正常和骨关节炎软骨进行原位酶谱分析,使用和不使用酶抑制剂,以确定II型胶原酶活性部位。使用35S标记的寡核苷酸探针检测配对样本中的MMP - 13 mRNA。进行比较分析。
原位酶谱分析显示,仅在骨关节炎软骨的软骨细胞上有II型胶原降解活性。其分布和量随软骨损伤程度和软骨细胞位置而变化,在深层软骨以及发生裂隙的软骨病变中最为明显。导致降解的酶表现为基质金属蛋白酶。MMP - 13 mRNA表达与II型胶原酶活性共分布。
在OA中,软骨细胞可降解II型胶原。随着软骨病变进展,II型胶原降解活性在部位和量上有所变化,并且始终与MMP - 13 mRNA表达共分布。